Plandai Biotechnology, Inc. Announces Distribution Agreement With Natural Products For Weight Management Product Using Phytofare™ Catechin Extract

SEATTLE, May 9, 2013 /PRNewswire/ -- Plandai Biotechnology, Inc. (OTCQB: PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, today announced a distribution agreement which grants Natural Products the exclusive rights in South Africa to develop and market a weight management product using Plandai's Phytofare™ Catechin Extract.  Natural Products specializes in producing and selling Maxi™ nutraceuticals through an Internet client base and directly to pharmacists and wellness retailers in South Africa.

Plandai's Phytofare™ Catechin Extract is processed to deliver a highly bioavailable, antioxidant-rich material to a level many times that of other green tea extracts available on the market.  Research has shown that green tea gallate catechins are extremely active antioxidants and in a bioavailable form, are able to protect the red and white blood cells against attack. While not a cure, Phytofare™ Catechin Extract offers meaningful disease prevention, particularly for patients suffering from a compromised immune system, through infections, viruses, malaria and other parasitic infections.

Green tea has long been recognized for its weight management benefits including fat reduction, increased metabolism and improved endurance during exercise.  These benefits will be the focus of the weight loss product using Phytofare™ Catechin Extract.    

"Natural Products is a dynamic and innovative South African company, and we believe it will excel in developing and marketing a weight loss product using Phytofare™ Catechin Extract," said Callum Baylis-Duffield, Vice-President and Global Director, Marketing Sales for Plandai Biotechnology. 

"We are excited to have the opportunity to work with Plandai on the development of this weight management product and believe it has tremendous potential in the South Africa market," said Warren Booth of Natural Products."

In published USDA studies, Plandai's proprietary plant extracts, including Phytofare™ Catechin Extract, Phytofare™ Glucoside Complex and Phytofare™ Carotenoid Extract, have shown to have improved bioavailability – the degree to which a substance becomes available to the target tissue after administration – of between 60-80%, far exceeding anything available today.  Superior levels of bioavailability simply mean that the body can actually receive the benefits promised on the product label.

The Company believes that its technology is the foundation for creating an entirely new family of drugs that can treat a multitude of diseases and conditions safely and affordably using naturally-derived extracts. 

About Plandai Biotechnology, Inc.

Plandai Biotechnology, Inc. and its subsidiaries develop highly bioavailable; phytonutrient rich extracts which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions.  Plandai Biotechnology controls every aspect of the process, from growing the raw materials on its farms in South Africa, to producing its patented Phytofare™ extracts in-house, allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process.  Targeted industries for the Company's products include beverage, cosmeceutical, wellness, nutraceutical, and pharmaceutical.  For more information, please visit http://www.plandaibiotech.com.

Safe Harbor Statement

The information provided may contain forward-looking statements and involve risks and uncertainties. Results, events and performances could vary from those contemplated. These statements involve risks and uncertainties which may cause actual results, expressed or implied, to differ from predicted outcomes. Risks and uncertainties include product demand, market competition, and Plandai's ability to meet current or future plans. Investors should study and understand all risks before making an investment decision. Readers are recommended not to place undue reliance on forward-looking statements or information. Plandai is not obliged to publicly release revisions to any forward-looking statement, to reflect events or circumstances afterward, or to disclose unanticipated occurrences, except as required under applicable laws.

Contact: 
Andrew Beyer
Phone: 619-202-7456
Email:  [email protected]

SOURCE Plandai Biotechnology, Inc.